سعر امريستاتين 40مجم 10 أقراص 2022

Simvastatin 40 mg film-coated tablets (Amristatin, Amriya, Egypt), an HMG-CoA reductase inhibitor (statin); 10 tablets per pack.

• To reduce the risk of total mortality (by reducing CHD death), non-fatal MI and stroke, and need for revascularisation in adults with established CHD, other atherosclerotic vascular disease or diabetes at high risk of coronary events (with diet).Population: AdultsDailyMed (U.S. National Library of Medicine)
• Adjunct to diet to reduce LDL-C in adults with primary hyperlipidaemia and in children/adolescents >=10 years with heterozygous familial hypercholesterolaemia; with other LDL-lowering therapy in homozygous FH.Population: Adults; paediatric >=10 years (HeFH)DailyMed (U.S. National Library of Medicine)
• Primary dysbetalipoproteinaemia and hypertriglyceridaemia in adults (adjunct to diet).Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions (>=5%): upper respiratory infection (9%), headache (7%), abdominal pain (7%), constipation (7%) and nausea (5%).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Concomitant strong CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, posaconazole, voriconazole, HIV/HCV protease inhibitors, clarithromycin, erythromycin, telithromycin, nefazodone, cobicistat-containing products).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Concomitant cyclosporine, danazol or gemfibrozil.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Acute liver failure or decompensated cirrhosis; hypersensitivity to simvastatin or any excipient.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Myopathy and rhabdomyolysis: risk increases with dose (myopathy about 0.61% with 80 mg in trials), age >=65, uncontrolled hypothyroidism, renal impairment and interacting drugs; advise patients to report unexplained muscle pain, tenderness or weakness; discontinue if CK is markedly elevated or myopathy is diagnosed.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Immune-mediated necrotising myopathy (autoimmune) has been reported rarely with statins.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hepatic dysfunction: persistent transaminase elevations can occur; check liver enzymes before starting and when clinically indicated; interrupt treatment if serious liver injury occurs.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Verapamil, diltiazem, dronedaroneDo not exceed simvastatin 10 mg daily (increased myopathy risk).DailyMed (U.S. National Library of Medicine)
• Amiodarone, amlodipine, ranolazineDo not exceed simvastatin 20 mg daily.DailyMed (U.S. National Library of Medicine)
• LomitapideReduce simvastatin dose by 50%; do not exceed 20 mg daily (or 40 mg in patients already on 80 mg chronically).DailyMed (U.S. National Library of Medicine)

• Discontinue simvastatin when pregnancy is recognised (or consider the patient's ongoing therapeutic needs); it may cause fetal harm based on its mechanism, as it decreases synthesis of cholesterol and possibly other biologically active substances derived from cholesterol.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Breastfeeding is not recommended during treatment with simvastatin.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Simvastatin: Prodrug hydrolysed to simvastatin acid, which inhibits HMG-CoA reductase, the rate-limiting enzyme converting HMG-CoA to mevalonate, a cholesterol precursor (US Zocor label).